Category: Accesswire

VANCOUVER, BC / ACCESS Newswire / February 13, 2026 / Gemdale Gold Inc. (TSXV:GEMG) (“Gemdale Gold” or the “Company“) is pleased to announce the closing of a strategic investment by Eldorado Gold Corporation (“Eldorado“) by way of a non-brokered private placement (the “Offering“).

The Offering consisted of the issuance of 2,000,000 units of the Company (the “Units“) at a price of C$1.20 per Unit for aggregate gross proceeds of C$2,400,000. Each Unit consists of one common share of the Company (a “Common Share“) and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at a price of C$1.50 for a period of 24 months from the date of issuance. No finder’s fees or commissions were paid in connection with the Offering. The gross proceeds of the Offering are intended to be used to advance the Company’s exploration properties in Finland and for general corporate purposes.

In connection with the Offering, the Company and Eldorado entered into an investor rights agreement (the “IRA“) pursuant to which Eldorado has been granted certain customary rights, including participation rights in future equity financings of the Company, a right of first refusal with respect to certain dispositions of project-level interests, and the right to appoint a representative to participate on a technical committee of the Company, each subject to customary conditions.

Dr. Toby Strauss, President and Chief Executive Officer of Gemdale Gold commented, “We are pleased to welcome Eldorado as a new shareholder and strategic partner. Their investment supports the continued advancement of our exploration portfolio in Finland, and we value the technical depth and operational experience they bring as we move into the next phase of growth for the Company”.

Completion of the Offering is subject to the receipt of all necessary regulatory approvals include the approval of the TSX Venture Exchange. The securities issued and issuable pursuant to the Offering are subject to a statutory hold period of four months and one day in accordance with applicable securities laws.

Early Warning Notice

Prior to the Offering, Eldorado did not beneficially own or control any Common Shares. Following the Strategic Investment, Eldorado beneficially owns and controls 2,000,000 Common Shares and 100,000,000 Warrants representing approximately 9.5% of the outstanding Common Shares on a non-diluted basis and approximately 13.6% on a partially diluted basis assuming full exercise of the Warrants. Eldorado’s acquisition of the Common Shares is for investment purposes. Eldorado has no current plans or intentions that relate to, or would result in, the matters listed in clauses (a) to (k) of Item 5 of Form 62-103F1 Required Disclosure Under the Early Warning Requirements. Eldorado may, subject to applicable law and depending on market and other conditions and the availability of other investment and business opportunities, increase or decrease its beneficial ownership of the Company’s securities, whether in the open market, by privately negotiated agreements or otherwise, or may develop such plans or intentions in the future. This disclosure is provided pursuant to Multilateral Instrument 62-104, which also requires an early warning report to be filed containing additional information with respect to the foregoing matters. A copy of the early warning report will be available on SEDAR+ under the Company’s issuer profile at www.sedarplus.ca and may be obtained upon request from Eldorado by contacting Eldorado at: 1188 – 550 Burrard Street, Bentall 5, Vancouver, British Columbia, V6C 2B5 Attention: Lynette Gould, VP, Investor Relations, Communications & External Affairs; Telephone number: 647 271 2827 or 1 888 353 8166.

About Eldorado Gold Corporation

Eldorado is a gold and base metals producer with mining, development and exploration operations in Canada, Greece and Türkiye. Eldorado has a highly skilled and dedicated workforce, safe and responsible operations, a portfolio of high-quality assets, and long-term partnerships with local communities. Eldorado’s common shares trade on the Toronto Stock Exchange (TSX: ELD) and the New York Stock Exchange (NYSE: EGO).

About Gemdale Gold

Gemdale Gold Inc. is a mineral exploration company focused on gold and critical minerals in Finland. Over the past eight years as a private company, the Company has assembled a portfolio of exploration licenses located in established and emerging mineral districts.

The Company’s flagship asset is the Pontio Gold Project in Western Finland, where more than 10,000 metres of drilling have been completed to date, primarily along the “M2 Trend”. Drilling has intersected near-surface gold mineralization along an interpreted strike length of approximately four kilometres. The Company intends to undertake an additional drill program to further delineate known zones of mineralization. Additional technical information about the Pontio Gold Project is contained in the Company’s technical report entitled “NI 43-101 Technical Report on the Pontio Project, Central Ostrobothnia, Finland“, available under the Company’s profile on SEDAR+.

The Company’s wholly owned principal projects include:

• Pontio Gold Project (Western Finland): Historical and recent drilling has outlined near-surface gold mineralization along a multi-kilometre trend that remains open along strike and at depth.

• Isoneva (Western Finland): Exploration stage gold project located proximal to extensive boulder train anomalies. The property is subject to an option agreement (the “Isoneva Option“) with Nordique Resources Inc. (“Nordique“) pursuant to which Nordique may earn a 100% interest by, among other things, funding exploration expenditures over a three-year period and making additional financial commitments to the Company. For more information on the Isoneva Option, please see the Company’s final long form prospectus dated January 30, 2026 under the heading “Business of the Corporation – January 1, 2025 to the date hereof“.

• Lapland Projects (Northern Finland): A group of exploration permits and applications located within a recognized gold and base-metal exploration region, in proximity to several recent regional discoveries.

• Kumiseva (Western Finland): Copper-nickel-platinum-palladium exploration license where historical government drilling has been completed.

• Savo / Rantasalmi (Southeastern Finland): Exploration license application area containing a historical inferred resource estimate prepared by a prior operator of 3.23 million tonnes grading 2.7 g/t gold for approximately 276,000 ounces of gold (see the Company’s news release dated May 15, 2023). The resource estimate is considered historical in nature, and a qualified person has not completed sufficient work to classify the historical estimate as current mineral resources or mineral reserves. The Company is not treating the historical estimate as current mineral resources or mineral reserves, and the historical estimate should not be relied upon.

Additional disclosure, including the Company’s financial statements, technical reports, news releases and other information, can be obtained at https://gemdalegold.com/ or on SEDAR+ at https://www.sedarplus.ca/home/#.

Qualified Person and NI 43-101 Disclosure

Dr. Toby Strauss (CGeol.; EurGeol.), Director, President and CEO is the Qualified Person as defined by National Instrument 43-101. Dr Strauss has verified the data supporting this news release and was the Qualified Person responsible for the referenced press releases. Dr. Strauss is responsible for the accuracy of technical information contained in this news release and has reviewed and approved the technical information contained within.

ON BEHALF OF GEMDALE GOLD INC

“Dr. Toby Strauss“

President & CEO

For Further Information Please Contact:

Mr. Paul Durham, MSc. Director and EVP Corporate Development Cell: +1 203-940 2538 Email: paul.durham@gemdale.eu

Mr. Patrick Chidley, MS, CFA Executive Chairman Cell: +1 917-991 7701 Email: patrick.chidley@gemdale.eu

or visit the Company website at www.gemdalegold.com.

Cautionary Note on Forward-Looking Information

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, statements regarding the Offering and the completion and use of proceed thereunder, the Company’s exploration and development plans, anticipated drill programs, potential mineralization, resource estimates, future financing plans, use of proceeds, regulatory approvals, market conditions and the Company’s future business objectives. Forward-looking information is generally identified by the use of words such as “plans,” “expects,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates,” “believes,” or variations of such words and phrases, or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” occur or be achieved.

Forward-looking information is based on a number of assumptions that management believes to be reasonable at the time such statements are made, including, without limitation, assumptions regarding the availability of capital, the receipt of required regulatory approvals, the continuation of favourable market conditions, the accuracy of historical and technical data, and the Company’s ability to execute its exploration and development plans as currently contemplated. However, forward‑looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking information. Such factors include, without limitation, risks related to exploration and development activities, commodity price fluctuations, availability of financing, regulatory approvals, environmental and permitting risks, operational risks, and general economic and market conditions.

Accordingly, readers should not place undue reliance on forward-looking information. Although the Company believes the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws.

SOURCE: Gemdale Gold Inc.

View the original press release on ACCESS Newswire

EUREKA, UT / ACCESS Newswire / February 13, 2026 / Applied Minerals, Inc., (the “Company”) a leading supplier of halloysite clay products marketed under the DRAGONITE^® trade name, is pleased to announce that on November 19, 2025 it successfully completed its financial restructuring process and emerged from Chapter 11.

Through its financial restructuring, the Company eliminated approximately $63 million of term debt and now has a virtually debt-free balance sheet. The Company is now positioned to expand its halloysite clay mining, processing and marketing activities. The Company experienced no operational disruptions during the Chapter 11 process.

Over the next few months, the Company expects to launch new grades of its DRAGONITE halloysite clay product.

Sample requests for the Company’s halloysite clay products should be submitted to info@appliedminerals.com.

About Applied Minerals

Applied Minerals, Inc. is a leading producer of halloysite clay products from its Dragon Mine property in Eureka, Utah. Halloysite is aluminosilicate clay with a unique tube-like morphology. The Company’s DRAGONITE halloysite clay products are used in applications such as, but not limited to, ceramics, molecular sieves, nucleating agents, catalysts, adhesives, coatings, flame-retardants and cosmetics.

Contact:

Chris Carney – President
(212) 226-4256
info@appliedminerals.com

SOURCE: Applied Minerals, Inc.

View the original press release on ACCESS Newswire

GREENSBORO, NORTH CAROLINA / ACCESS Newswire / February 13, 2026 / Network Wireless Solutions (NWS) today announced a planned leadership succession designed to support the company’s continued growth and long-term value creation.

Effective March 1, Dr. Louis J. Hutchinson, III, currently President and Chief Revenue Officer, will assume the role of Interim Chief Executive Officer. Xavier Williams will transition out of the CEO role on February 28, following four years of impactful leadership and more than 35 years in the communications industry.

During Williams’ tenure, NWS transformed from a U.S.-based mobility distributor into a scaled North American digital infrastructure platform spanning mobility, broadband, and data center solutions. The company successfully integrated two acquisitions, expanded its geographic footprint, launched new business lines, and, over the past year, meaningfully grew revenue and EBITDA.

“It has been a privilege to help lead NWS through a period of significant transformation,” said Williams. “We have strengthened the platform, enhanced our market position, and built a team poised for sustained growth. Lou is well positioned to lead the company forward.”

Dr. Hutchinson has been instrumental in driving NWS’ recent momentum, leading enterprise-wide revenue initiatives and strengthening commercial execution across operations, sales, and marketing.

“We are entering our next phase from a position of strength,” said Hutchinson. “NWS has a differentiated platform, strong customer demand, and meaningful growth opportunities ahead. Our focus remains on executing our strategy and expanding our leadership in integrated cloud distribution and digital infrastructure.”

With a strengthened operating foundation and clear strategic priorities, NWS remains well positioned to drive sustainable growth and continued value creation.

About Network Wireless Solutions
Network Wireless Solutions (NWS) is a leading provider of digital infrastructure, network solutions, and more. The company is committed to delivering reliable, innovative solutions that support its customers’ evolving needs. As a nimble and reliable distributor, NWS serves telcos, wireless carriers, ISPs, WISPs, data centers, and utilities with innovative solutions tailored to their network needs. From FTTx and DAS to Private Wireless Networks, Fixed Wireless Access, and Network Testing Equipment, we deliver reliable, future-ready solutions backed by world-class vendor partnerships. For more information, visit nwsnext.com.

Media Contact:
Tiffani Swain
Head of Marketing & Communications (CMCO)
Network Wireless Solutions
984.301.1235
tiffani.swain@nwsnext.com

SOURCE: NWS

View the original press release on ACCESS Newswire

ST. GEORGE’S, NEWFOUNDLAND AND LABRADOR / ACCESS Newswire / February 13, 2026 / Atlas Salt Inc. (“Atlas Salt” or the “Company”) (TSXV:SALT)(OTCQX:SALQF)(FRA:9D00) announces an expansion of its strategic relationship with Sandvik Mining (“Sandvik”) in connection with the Updated Feasibility Study (“UFS”) for the Great Atlantic Salt Project (the “Project”), located near St. George’s, Newfoundland and Labrador.

Building on the comprehensive non-binding Memorandum of Understanding (“MOU”) announced in September 2024, Atlas Salt and Sandvik have expanded the scope of the MOU to reflect the full construction and ramp-up requirements outlined in the UFS. The expanded scope contemplates Sandvik supplying underground mobile mining equipment, technology, and associated services, with vendor-supported financing for Sandvik capital equipment required during Project construction and the planned ramp-up to steady-state production of 4.0 million tonnes per year (“Mtpa”).

Nolan Peterson, President and CEO of Atlas Salt, commented:

“The Updated Feasibility Study reflects the scale and longevity of the Great Atlantic Salt Project, and our relationship with Sandvik has evolved accordingly. What began as an equipment supply arrangement has developed into a long-term strategic partnership aligned with construction, ramp-up, and decades of expected operations. This partnership supports execution certainty, operational readiness, and the disciplined development of the Project.”

Peter Corcoran, Vice President of Sandvik Mining Canada added:

“Sandvik is pleased to continue working with Atlas Salt as the Great Atlantic Salt Project advances. The UFS confirms a long-term vision that aligns well with our portfolio of electrified equipment, automation, and lifecycle services, and our strategic initiatives in the Canadian market. We look forward to continuing to support the Project through its development and operation.”

Expanded Scope of the Sandvik Relationship

Based on the mine plan, production profile, and capital assumptions presented in the UFS, the anticipated commercial value of Sandvik-supplied equipment, technology, and services during the construction and ramp-up phases of the Project is estimated at approximately $132 million, representing an increase of $59 million from the $73 million contemplated under the original MOU.

The estimated $132 million scope includes:

• Underground mobile mining equipment and associated services required for mine construction and initial operations.

• Additional fleet units, electrification, automation, and digital systems deployed during the multi-year ramp-up to full production capacity.

• Equipment quantities and deployment schedules consistent with the UFS development plan and ramp-up timelines post-construction.

In connection with the product and service offering, Sandvik has expressed a non-binding financing arrangement to support the acquisition of certain Sandvik capital equipment, advanced mining system and technology contemplated in the UFS. The terms of financing remain subject to customary due diligence, receipt of Sandvik’s required internal approvals, and negotiation and execution of the definitive agreements.

Alignment with Project Execution Strategy

Sandvik continues its role as an Integrated Project Delivery (“IPD”) partner in supporting Atlas Salt’s UFS and execution strategy by aligning mine design, equipment selection, automation, and maintenance planning with the Project’s safety, productivity, and sustainability objectives.

The UFS contemplates a predominantly electric and battery-electric underground fleet, supported by automation and digital systems, as a core element of the Project’s operating strategy. Sandvik’s technology platform, including AutoMine®, digital fleet management tools, and battery solutions, is expected to support these objectives while reducing operating risk and improving long-term cost certainty. Operating with Sandvik’s battery electric and electric underground fleet, as contemplated in the UFS, is expected to reduce diesel emissions, underground heat load, and ventilation demand, resulting in lower greenhouse gas emissions, improved working conditions, and reduced energy intensity over the life of the Project.

Options Grant

The Company also announces that, subject to approval of the TSX Venture Exchange (the “Exchange”), the Board of Directors has approved the issuance of incentive stock options (the “Options”) to certain directors, officers, employees and consultants of the Company pursuant to the Company’s existing 10% rolling stock option plan (the “Stock Option Plan”).

A total of 3,150,000 Options have been granted. Each Option entitles the holder to purchase one (1) common share in the capital of the Company (each, a “Share”) at an exercise price of $0.98 per Share, which is equal to or greater than the market price of the Company’s common shares on the date of grant. The Options are exercisable for a period of five years from the date of grant for directors and officers and will expire on February 12, 2031, subject to the terms of the Stock Option Plan. The Options granted to all others are exercisable for a period of three years from the date of grant and will expire on February 12, 2029, subject to the terms of the Stock Option Plan.

The Options will be issued as follows:

• Directors: 1,200,000 Options

• Officers: 1,000,000 Options

• Employees: 550,000 Options

• Consultants: 400,000 Options

All Options granted are subject to vesting periods of either one or two years.

The Company confirms that the Options are being granted for future services and that the recipients are bona fide directors, officers, employees or consultants of the Company in accordance with applicable Exchange requirements.

After the issuance of the Options, 2,693,611 options will remain available for issuance under the Stock Option Plan.

Market Maker

The Company further announces that it has retained Integral Wealth Securities Limited (“Integral”) to provide Market-Making services in accordance with Exchange policies. Integral will trade securities of Atlas Salt on the TSX Venture Exchange for the purpose of maintaining an orderly market for the Company’s securities.

The agreement between the Company and Integral (the “Agreement”), executed on November 19, 2025, is for an initial term of three months. The Agreement outlines that Integral will receive compensation of CAD$6,000 per month, with the first monthly payment paid on the signing of the Agreement by the Company, and thereafter, the fee will be payable on the first day of each month. After the third month, the Company may terminate the Agreement on 30 days written notice. There are no performance factors in the agreement and Integral will not receive shares or options as compensation.

Atlas Salt and Integral are unrelated and unaffiliated entities; Integral is a member of the Canadian Investment Regulatory Organization (“CIRO”) and can access all Canadian Stock Exchanges and Alternative Trading Systems. The capital and securities required for any trade undertaken by Integral as principal will be provided by Integral.

For further information and ongoing updates, please visit https://atlassalt.com.

For further information about Sandvik, please visit https://www.rocktechnology.sandvik/

About Sandvik Mining

Sandvik Mining is the mining-focused business area of the global Sandvik Group, and a leading supplier of equipment, tools, parts, services, digital solutions, and technologies designed to enhance productivity, safety, and sustainability in the mining and infrastructure industries. Application areas include rock drilling, rock cutting, loading and hauling, tunneling, and quarrying. In 2024, Sandvik Mining and Rock Solutions reported revenues of approximately SEK 63.6 billion and employed roughly 17,300 people worldwide. Sandvik AB, the parent company headquartered in Stockholm, Sweden, operates in more than 150 countries with total Group revenues of about SEK 123 billion and approximately 41,000 employees.

About Integral Wealth Securities Limited

Integral Wealth Securities Limited is an independent CIRO-licensed investment dealer engaged in market making, investment banking and wealth management. Headquartered in Toronto, the firm operates from nine offices across Canada. The firm’s FINRA-licensed US broker dealer affiliate, Integral Wealth Securities LLC, is based in Malvern, PA and provides investment banking as well as private placement services.

About Atlas Salt

Atlas Salt is developing Canada’s next salt mine and is committed to responsible and sustainable mining practices. With a focus on innovation and efficiency, the company is poised to make significant contributions to the North American salt market while upholding its values of environmental stewardship and community engagement.

For information, please contact:

Jeff Kilborn, CFO & VP Corporate Development
investors@atlassalt.com
(709) 275-2009

We seek safe harbour.

Cautionary Statement

Neither the TSX Venture Exchange nor its Regulation Services Provider, (as the term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements in this press release relate to, among other things: obtaining financing, completion, delivery and timing of project components and requirements, and analysis and assumptions related thereto. Actual future results may differ materially. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, technical, economic, and competitive uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the timing, completion and delivery of required permits, supply arrangements and financing. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times. Except as required by law, the Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

SOURCE: Atlas Salt Inc.

View the original press release on ACCESS Newswire

New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform

ESTERO, FL / ACCESS Newswire / February 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the appointment of Phillip Balatsos to its Board of Directors, effective February 6, 2026. The appointment follows the planned departures of Suren Ajjarapu and Donald G. Fell, from the board.

“On behalf of our Board, I am delighted to welcome Phillip to the Aspire Biopharma Board. His leadership experience will provide invaluable guidance as the organization continues to evolve and strengthen,” said Kraig Higginson, Interim CEO and Chairperson of the Aspire Biopharma Board. “We are confident that his insights will help accelerate our strategy of reformulating established drugs with large markets and reinforce the Company’s commitment to patients, customers, and shareholders.”

Phillip Balatsos is a senior financial markets executive and board director with over 25 years of experience across foreign exchange, emerging markets, institutional sales and trading, and public company governance. He has held leadership roles at global financial institutions including Barclays Capital, Credit Suisse, and XP Investments, and currently operates within an independent trading platform at Oscar Gruss & Son.

In addition to his capital markets career, Mr. Balatsos brings entrepreneurial and operating experience, having founded and scaled a multi-location hospitality business and advised national restaurant groups on procurement, pricing, and operational efficiency. This background provides a pragmatic operator’s perspective on margins, cost structures, and execution-particularly valuable in growth and turnaround environments.

Mr. Balatsos currently serves on the Boards of Directors of Inspire Veterinary Partners, Inc., where he is a member of the Audit Committee, and Ciso Global, Inc., a cybersecurity and risk management company. He previously served on the Board of Sadot Group Inc., contributing to its transformation from a restaurant operator into a global agri-commodity trading and food supply chain business, and serving on both the Audit and Executive Compensation Committees.

He holds a Bachelor of Science in Business Administration from Skidmore College, with a minor in International Relations and a concentration in Spanish.

Phillip Balatsos will serve on the Audit and Compensation Committees.

“The Company’s mission to provide rapid-onset therapeutics through novel sublingual formulations resonates strongly with my experience in scaling growth-stage companies,” said Mr. Balatsos. “I look forward to supporting this team as they advance their platform and drive the next phase of growth and innovation.”

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)

Reports full-year revenue of $1.9 billion, GAAP net loss of $(2.8) billion and GAAP diluted EPS of $(7.26)

Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026

Announces influenza vaccine filing accepted for regulatory review in the EU, Canada and Australia; Company received Refusal-to-File letter from U.S. FDA and has requested Type A meeting to understand path forward

Announces Norovirus Phase 3 trial fully enrolled with a data readout expected in 2026

Announces full enrollment of Phase 2 intismeran autogene trial in muscle invasive bladder cancer

CAMBRIDGE, MA / ACCESS Newswire / February 13, 2026 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter of 2025.

“In 2025, we sharpened our commercial execution, launched our third product and brought online three international manufacturing sites, while advancing our mRNA pipeline. At the same time, we lowered our annual operating expenses by approximately $2.2 billion, significantly surpassing our cost-reduction targets,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We entered the new year with strong momentum despite the continued challenging environment in the U.S., poised to deliver up to 10 percent revenue growth through mNEXSPIKE expansion and our international strategic partnerships. We look forward to delivering multiple potential product approvals and late-stage clinical readouts, while driving continued innovation across our mRNA platform.”

Commercial Updates

Moderna is entering the year with three approved products, Spikevax^®, mNEXSPIKE^® and mRESVIA^®, with seasonal vaccines expected to deliver up to 10% revenue growth in 2026. In line with its strategy to drive growth through geographic expansion and new product launches, the Company recently announced long-term agreements with Mexico and Taiwan for respiratory vaccines, received regulatory approvals in Canada and Australia for mNEXSPIKE, and the strain-updated Spikevax vaccine was authorized in the UK for use in the spring vaccination campaign. The Company also announced a strategic collaboration with Recordati to globally commercialize Moderna’s propionic acidemia candidate.

Fourth Quarter 2025 Financial Results

Revenue: Total revenue for the fourth quarter of 2025 was $678 million, on the higher end of the Company’s prior expectations, and was driven primarily by COVID vaccine sales. Product sales were $264 million in the U.S. and $381 million in international markets. Fourth quarter revenue decreased 30% compared to the same period in 2024, primarily reflecting lower COVID vaccine sales volume compared to the prior-year period.

Cost of Sales: Cost of sales for the fourth quarter of 2025 was $452 million, including third-party royalties of $34 million and inventory write-downs of $144 million. Cost of sales decreased 39% compared to the same period in 2024, primarily reflecting lower contract manufacturing wind-down costs and inventory write-downs.

Research and Development Expenses: Research and development expenses for the fourth quarter of 2025 were $775 million, a 31% decrease compared to the same period in 2024. The decrease was driven primarily by lower clinical development and manufacturing costs, reflecting the wind-down of large Phase 3 respiratory programs, continued portfolio prioritization and cost discipline across the organization.

Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of 2025 were $308 million, a 12% decrease compared to the same period in 2024. The decline was primarily driven by reductions in consulting and external services across multiple functions, reflecting continued discipline across the organization.

Income Taxes: Income tax provisions for both periods were not material, as the Company continues to maintain a global valuation allowance against most of its deferred tax assets.

Net Loss: Net loss was $(826) million for the fourth quarter of 2025, compared to net loss of $(1.1) billion for the fourth quarter of 2024.

Loss Per Share: Loss per share was $(2.11) for the fourth quarter of 2025, compared to loss per share of $(2.91) for the fourth quarter of 2024.

Full Year 2025 Financial Results

Revenue: Total revenue for the full year 2025 was $1.9 billion, a 40% decrease compared to 2024, with the majority generated from COVID vaccine sales, along with $126 million of other revenue. U.S. revenue totaled $1.2 billion, while revenue from international markets was $745 million. The year-over-year decrease primarily reflected lower COVID vaccine sales volume across all regions. During 2025, the Company also began recognizing stand-ready manufacturing revenue related to its long-term strategic partnerships, which is reported in other revenue.

Cost of Sales: Cost of sales for the full year 2025 was $868 million, including third-party royalties of $88 million and inventory write-downs of $291 million. Cost of sales decreased 41% compared to 2024, driven primarily by manufacturing productivity and operational efficiencies, lower inventory write-downs, lower contract manufacturing wind-down costs, and lower sales volume.

Research and Development Expenses: Research and development expenses for the full year 2025 were $3.1 billion, a 31% decrease compared to 2024. The decrease was driven primarily by lower clinical development and manufacturing costs, reflecting the wind-down of large Phase 3 respiratory programs, continued portfolio prioritization and cost discipline across the organization. These decreases were partially offset by increased investment in the Company’s norovirus vaccine and oncology programs. In addition, 2024 included costs related to the purchase of two priority review vouchers, which did not recur in 2025.

Selling, General and Administrative Expenses: Selling, general and administrative expenses for the full year 2025 were $1.0 billion, a 13% decrease compared to 2024. The decrease was driven primarily by lower consulting and external services, along with reduced spending across multiple functions and operating areas, while the Company continued to invest in supporting its commercial operations and broader business activities.

Income Taxes: Income tax provisions for both periods were not material, as the Company continues to maintain a global valuation allowance against most of its deferred tax assets.

Net Loss: Net loss for the full year 2025 was $2.8 billion, compared to $3.6 billion for the full year 2024.

Loss Per Share: Loss per share for the full year 2025 was $(7.26), compared to $(9.28) for the full year 2024.

Cash Position: Cash, cash equivalents and investments as of December 31, 2025, were $8.1 billion, compared to compared to $9.5 billion as of December 31, 2024. The year-end balance included a $600 million initial draw on the Company’s $1.5 billion credit facility, with the year-over-year decrease primarily driven by operating losses associated with continued investment in research and development and advancement of the Company’s pipeline.

2026 Financial Framework

Revenue: The Company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international.

Cost of Sales: Cost of sales for 2026 is expected to be approximately $0.9 billion.

Research and Development Expenses: Research and development expenses for 2026 are anticipated to be approximately $3.0 billion.

Selling, General and Administrative Expenses: Selling, general and administrative expenses for 2026 are projected to be approximately $1.0 billion.

Income Taxes: The Company expects its full-year tax expense to be negligible.

Capital Expenditures: Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion.

Cash and Investments: Year-end cash and investments for 2026 are projected to be $5.5 to $6.0 billion. Excludes any additional draw down from the Company’s credit facility.

Recent Progress and Upcoming Late-Stage Pipeline Milestones

Infectious disease vaccines:

• Norovirus vaccine: Moderna’s ongoing Phase 3 safety and efficacy study of mRNA-1403 is fully enrolled in a second Northern Hemisphere season (2025-2026) with a data readout expected in 2026, subject to case accruals.

Oncology therapeutics:

• mRNA-4359: Moderna’s Phase 1/2 study of mRNA-4359, an investigational wholly-owned cancer antigen therapy, is ongoing. The Phase 2 portion of the study includes cohorts in first-line metastatic melanoma, second-line+ metastatic melanoma and first-line metastatic NSCLC, and the Company expects a potential Phase 2 data readout in 2026.

Rare disease therapeutics:

• Methylmalonic acidemia (MMA) therapeutic: Moderna’s mRNA-3705 has been selected by the FDA for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, with a registrational study expected to begin in 2026.

Moderna Corporate Updates

• Scheduled the Moderna Annual Meeting of Shareholders to be held on Wednesday, May 6, 2026, at 8:00 a.m. ET.

Company Accolades

• Moderna was recognized by TIME as one of America’s Most Iconic Companies.

Key 2026 Investor and Analyst Event Dates

• Analyst Day: November 12

Investor Call and Webcast Information

Moderna will host a live conference call and webcast at 8:00 a.m. ET on February 13, 2026. To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers and a unique pin number will be provided. A live webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website.

• Telephone: https://register-conf.media-server.com/register/BIf7fdfaa3a1354d55999e80cdd7546c62

• Webcast: https://investors.modernatx.com

The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in millions, except per share data)

		Three Months Ended December 31,								Years Ended December 31,
		2025				2024				2025				2024
Revenue:
Net product sales		$	645			$	938			$	1,818			$	3,109
Other revenue1			33				28				126				127
Total revenue			678				966				1,944				3,236
Operating expenses:
Cost of sales			452				739				868				1,464
Research and development			775				1,122				3,132				4,543
Selling, general and administrative			308				351				1,018				1,174
Total operating expenses			1,535				2,212				5,018				7,181
Loss from operations			(857	)			(1,246	)			(3,074	)			(3,945	)
Interest income			70				91				314				425
Other expense, net			(12	)			(29	)			(8	)			(87	)
Loss before income taxes			(799	)			(1,184	)			(2,768	)			(3,607	)
Provision for (benefit from) income taxes			27				(64	)			54				(46	)
Net loss		$	(826	)		$	(1,120	)		$	(2,822	)		$	(3,561	)
Net loss per share
Basic and Diluted		$	(2.11	)		$	(2.91	)		$	(7.26	)		$	(9.28	)
Weighted average common shares used in calculation of net loss per share
Basic and Diluted			392				385				389				384

_______

¹Includes grant, collaboration, licensing and royalty, and stand-ready manufacturing revenue.

MODERNA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in millions)

		December 31,				December 31,
		2025				2024
Assets
Current assets:
Cash and cash equivalents		$	2,595			$	1,927
Investments			3,204				5,098
Accounts receivable, net			184				358
Inventory			153				117
Prepaid expenses and other current assets			408				599
Total current assets			6,544				8,099
Investments, non-current			2,336				2,494
Property, plant and equipment, net			2,134				2,196
Right-of-use assets, operating leases			719				759
Other non-current assets			605				594
Total assets		$	12,338			$	14,142
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	317			$	405
Accrued liabilities			1,386				1,427
Deferred revenue			99				153
Other current liabilities			185				221
Total current liabilities			1,987				2,206
Deferred revenue, non-current			153				58
Operating lease liabilities, non-current			653				671
Financing lease liabilities, non-current			20				39
Long-term debt			590				–
Other non-current liabilities			285				267
Total liabilities			3,688				3,241
Stockholders’ equity:
Additional paid-in capital			1,382				866
Accumulated other comprehensive income (loss)			45				(10	)
Retained earnings			7,223				10,045
Total stockholders’ equity			8,650				10,901
Total liabilities and stockholders’ equity		$	12,338			$	14,142

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in millions)

		Years Ended December 31,
		2025				2024
Operating activities
Net loss		$	(2,822	)		$	(3,561	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			483				429
Depreciation and amortization			215				189
Amortization/accretion of investments			(67	)			(95	)
Loss on equity investments, net			8				52
Other non-cash items			77				60
Changes in assets and liabilities:
Accounts receivable, net			156				534
Prepaid expenses and other assets			153				145
Inventory			(34	)			83
Right-of-use assets, operating leases			38				(53	)
Accounts payable			(92	)			(69	)
Accrued liabilities			(2	)			(385	)
Deferred revenue			41				(439	)
Operating lease liabilities			(21	)			28
Other liabilities			(6	)			78
Net cash used in operating activities			(1,873	)			(3,004	)
Investing activities
Purchases of marketable securities			(5,768	)			(6,529	)
Proceeds from maturities of marketable securities			5,563				5,562
Proceeds from sales of marketable securities			2,353				3,967
Purchases of property, plant and equipment			(192	)			(1,051	)
Purchase of intangible asset			(10	)			–
Net cash provided by investing activities			1,946				1,949
Financing activities
Proceeds from credit facility			600				–
Payments of credit facility issuance costs			(22	)			–
Proceeds from issuance of common stock through equity plans			35				66
Tax payments related to net share settlements on equity awards			(2	)			–
Changes in financing lease liabilities			(18	)			(10	)
Net cash provided by financing activities			593				56
Effect of changes in exchange rates on cash and cash equivalents			2				–
Net increase (decrease) in cash, cash equivalents and restricted cash			668				(999	)
Cash, cash equivalents and restricted cash, beginning of year			1,929				2,928
Cash, cash equivalents and restricted cash, end of period		$	2,597			$	1,929

Spikevax^®, mRESVIA^® and mNEXSPIKE^® are registered trademarks of Moderna.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s 2026 financial framework, including its plan to deliver up to 10% revenue growth and GAAP operating expense reductions, and its projected year-end cash balance; Moderna’s commercial growth drivers, including geographic expansion and new product launches; Moderna’s continued cost discipline; anticipated mNEXSPIKE expansion; Moderna’s international strategic partnerships; potential mRNA-4157 Phase 3 adjuvant melanoma data in 2026; the potential of Moderna’s expanded oncology portfolio; pending and anticipated regulatory filings and potential approvals, including timing of approvals; Moderna’s strategic collaboration with Recordati; Moderna’s requested Type A meeting to understand the path forward for mRNA-1010; and anticipated progress and milestones for Moderna’s pipeline programs, including potential near-term data readouts and other catalysts. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

###

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

(NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL)

SAINT HELIER, JE / ACCESS Newswire / February 13, 2026 / Caledonia Mining Corporation Plc (“Caledonia” or “the Company”) announces that it received notification on February 11, 2026 from BlackRock, Inc. that on February 10, 2026 it had crossed a threshold for notification of a relevant change (as defined by the AIM Rules for Companies).

A copy of the notification is below.

Enquiries:

Caledonia Mining Corporation Plc Mark Learmonth Camilla Horsfall	Tel: +44 1534 679 800 Tel: +44 7817 841 793
Cavendish Capital Markets Limited (Nomad and Broker) Adrian Hadden George Lawson	Tel: +44 207 397 1965 Tel: +44 131 220 9775
Camarco, Financial PR (UK) Gordon Poole Elfie Kent	Tel: +44 20 3757 4980
Curate Public Relations (Zimbabwe) Debra Tatenda	Tel: +263 77802131
IH Securities (Private) Limited (VFEX Sponsor – Zimbabwe) Lloyd Mlotshwa	Tel: +263 (242) 745 119/33/39

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:			CALEDONIA MINING CORPORATION PLC
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments						X
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name			BlackRock, Inc.
City and country of registered office (if applicable)			Wilmington, DE, USA
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi:			10/02/2026
6. Date on which issuer notified (DD/MM/YYYY):			11/02/2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached	5.57%	1.30%		6.88%	1,329,520
Position of previous notification (if applicable)	5.57%	1.57%		7.14%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
JE00BF0XVB15				1,076,855					5.57%
SUBTOTAL 8. A		1,076,855					5.57%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date x	Exercise/ Conversion Period xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
Securities Lending		N/A	N/A			136,809			0.70%
			SUBTOTAL 8. B 1			136,809			0.70%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date x		Exercise/ Conversion Period xi		Physical or cash Settlement xii			Number of voting rights	% of voting rights
CFD	N/A		N/A		Cash			115,857	0.60%
					SUBTOTAL 8.B.2			115,857	0.60%

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv				X
Name xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock International Holdings, Inc.
BR Jersey International Holdings L.P.
BlackRock (Singapore) Holdco Pte. Ltd.
BlackRock HK Holdco Limited
BlackRock Lux Finco S.a.r.l.
BlackRock Japan Holdings GK
BlackRock Japan Co., Ltd.
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
Trident Merger, LLC
BlackRock Investment Management, LLC
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock International Holdings, Inc.
BR Jersey International Holdings L.P.
BlackRock Holdco 3, LLC
BlackRock Cayman 1 LP
BlackRock Cayman West Bay Finco Limited
BlackRock Cayman West Bay IV Limited
BlackRock Group Limited
BlackRock Investment Management (UK) Limited
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock International Holdings, Inc.
BR Jersey International Holdings L.P.
BlackRock Australia Holdco Pty. Ltd.
BlackRock Investment Management (Australia) Limited
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock Holdco 4, LLC
BlackRock Holdco 6, LLC
BlackRock Delaware Holdings Inc.
BlackRock Institutional Trust Company, National Association
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock Holdco 4, LLC
BlackRock Holdco 6, LLC
BlackRock Delaware Holdings Inc.
BlackRock Fund Advisors	3.05%	0.010%	3.07%
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock International Holdings, Inc.
BlackRock Canada Holdings ULC
BlackRock Asset Management Canada Limited
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock Capital Holdings, Inc.
BlackRock Advisors, LLC
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
BlackRock Holdco 2, Inc.
BlackRock Financial Management, Inc.
BlackRock International Holdings, Inc.
BR Jersey International Holdings L.P.
BlackRock Holdco 3, LLC
BlackRock Cayman 1 LP
BlackRock Cayman West Bay Finco Limited
BlackRock Cayman West Bay IV Limited
BlackRock Group Limited
BlackRock Advisors (UK) Limited
BlackRock, Inc.
BlackRock Saturn Subco, LLC
BlackRock Finance, Inc.
Trident Merger, LLC
BlackRock Investment Management, LLC
Amethyst Intermediate, LLC
Aperio Holdings, LLC
Aperio Group, LLC
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
BlackRock Regulatory Threshold Reporting Team Jana Blumenstein 020 7743 3650

Place of completion	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
Date of completion	11 February 2026

SOURCE: Caledonia Mining Corporation Plc

View the original press release on ACCESS Newswire